These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24269566)

  • 1. Etrolizumab: anti-β7-a novel therapy for ulcerative colitis.
    Lin KK; Mahadevan U
    Gastroenterology; 2014 Jan; 146(1):307-9. PubMed ID: 24269566
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
    Rutgeerts PJ; Fedorak RN; Hommes DW; Sturm A; Baumgart DC; Bressler B; Schreiber S; Mansfield JC; Williams M; Tang M; Visich J; Wei X; Keir M; Luca D; Danilenko D; Egen J; O'Byrne S
    Gut; 2013 Aug; 62(8):1122-30. PubMed ID: 22717454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
    Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT
    J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary: outcomes after escalation of infliximab in moderately active ulcerative colitis.
    Halpin S; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Apr; 35(8):957-8; discussion 958-9. PubMed ID: 22436036
    [No Abstract]   [Full Text] [Related]  

  • 5. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab therapy for ulcerative colitis: many unanswered questions.
    Present DH
    Am J Gastroenterol; 2001 Aug; 96(8):2294-6. PubMed ID: 11513164
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?
    Ben-Horin S
    Gastroenterology; 2015 Jun; 148(7):1268-71. PubMed ID: 25921372
    [No Abstract]   [Full Text] [Related]  

  • 8. [Adapting the dose to the residual concentration of infliximab in cryptogenic inflammatory diseases of the intestines].
    Chanson P; Pariente A
    Rev Prat; 2015 Apr; 65(4):473. PubMed ID: 26058185
    [No Abstract]   [Full Text] [Related]  

  • 9. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
    Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME
    Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Hendy P; Hart A
    Aliment Pharmacol Ther; 2015 Jan; 41(1):149. PubMed ID: 25483435
    [No Abstract]   [Full Text] [Related]  

  • 11. Is keeping the colon the ultimate marker of success in ulcerative colitis?
    Nguyen GC; Prather CM
    Gastroenterology; 2009 Oct; 137(4):1204-6. PubMed ID: 19717125
    [No Abstract]   [Full Text] [Related]  

  • 12. [Management of severe attack of ulcerative colitis].
    Tysk C; Almer S; Andersson MV; Befrits R; Hertervig E; Kilander A; Lindgren S; Suhr O
    Lakartidningen; 2009 Nov 4-12; 106(45):2994-8. PubMed ID: 19998825
    [No Abstract]   [Full Text] [Related]  

  • 13. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
    Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biological therapy in children with inflammatory bowel syndrome (clinical cases)].
    Alieva ÉI
    Eksp Klin Gastroenterol; 2014; (1):110-2. PubMed ID: 25518466
    [No Abstract]   [Full Text] [Related]  

  • 15. Infliximab for refractory ulcerative colitis.
    Chey WY; Hussain A; Ryan C; Potter GD; Shah A
    Am J Gastroenterol; 2001 Aug; 96(8):2373-81. PubMed ID: 11513177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.
    Oussalah A; Evesque L; Laharie D; Roblin X; Boschetti G; Nancey S; Filippi J; Flourié B; Hebuterne X; Bigard MA; Peyrin-Biroulet L
    Am J Gastroenterol; 2010 Dec; 105(12):2617-25. PubMed ID: 20736936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
    Sandborn WJ; Rutgeerts P; Feagan BG; Reinisch W; Olson A; Johanns J; Lu J; Horgan K; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF
    Gastroenterology; 2009 Oct; 137(4):1250-60; quiz 1520. PubMed ID: 19596014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis.
    Kevans D; Waterman M; Milgrom R; Xu W; Van Assche G; Silverberg M
    J Gastroenterol Hepatol; 2015 Jan; 30(1):64-70. PubMed ID: 25041458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
    Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C
    Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.